Day: May 6, 2024

Data from the Icahn School of Medicine at Mount Sinai and Potomac Urology presented at the 2024 AUA Annual Meeting highlight Aquablation therapy’s potential to become the new standard of care in BPH for prostates of all sizes SAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) — PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced long-term, real-world data showcasing the benefits of Aquablation therapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) at both academic and commercial settings. The results were presented this past weekend at the American Urological Association (AUA) Annual Meeting in San Antonio, Texas. “The data presented at AUA confirm the safety and long-term...

SAN MATEO, Calif., May 06, 2024 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024. “We are thrilled to welcome Thierry to our executive leadership team in the role of CFO. Thierry brings a proven track record in corporate finance in the biopharmaceutical sector, bringing expertise in corporate planning and strategy, investor relations, financing, and M&A,” said Dave Happel, CEO of Sagimet. “Having an experienced leadership team with the appropriate skillsets is critical at this key stage as we advance denifanstat into a registrational Phase...

HANOVER, Md., May 06, 2024 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced that management will be participating in the EF Hutton Annual Global Conference being held May 15, 2024 at The Plaza Hotel in New York City. Management will be holding one-on-one meetings with investors. About Processa Pharmaceuticals, Inc. Processa is a clinical-stage pharmaceutical company focused on developing the Next Generation Chemotherapy (NGC) drugs to improve the safety and efficacy of cancer treatment. By combining its novel oncology pipeline with proven cancer-killing active molecules and the Processa Regulatory Science Approach, as well as...

Fingerprints today announced that the company has signed a patent license agreement with a major global company as the licensee. This represents a milestone as Fingerprints’ first-ever patent license agreement, arising from the New Business team initiative which was announced in July 2023 with the aim of developing new business and driving revenue growth. One of the focus areas for the New Business unit is the monetization of our strong portfolio of intellectual property rights (IPR). We see an increased potential in this area, and we work with leading patent law firms to capitalize on this opportunity. “Fingerprints has over 700 registered patents in its portfolio, extending from algorithms and biometric image processing through to sensors and hardware packaging technology. A smaller part of this patent portfolio pertains to a field outside...